In-Silico and In-Vitro Evaluation of the Anti-Diabetic Activity of Gmelinol

Abstract

Purpose The present study was investigated the anti-diabetic activity of Gmelinol using the in-silico molecular docking and in-vitro study. Methods In-silico study was performed using TriposSybyl-X 2.0 (TriposInc, St Louis, MO, USA) software and the evaluation was conducted based on the total score and visualization. In-vitro study was performed using the α-amylase inhibitory assay and α-glucosidase inhibitory assay and measured the percentage inhibition of the enzyme. The glucose uptake assay was also performed using L6 myoblast cell and measured the glucose utilization. Results Molecular docking studies demonstrated that Gmelinol was able to bind the active sites of proteins and the total score of Gmelinol with α-amylase and α-glucosidase were found 6.33 and 5.04 respectively. Gmelinol showed significant α-amylase and α-glucosidase inhibitory activities (IC50 = 45.92 µg/mL on α-amylase and IC50 = 49.25 µg/mL on α-glucosidase) compare with Acarbose (IC50 = 70.63 µg/mL α-amylase and IC50 = 64.82 µg/mL on α-glucosidase). Gmelinol showed significant glucose utilization activities in the L6 myoblast cell. Conclusion Gmelinol has shown anti-diabetic activity in terms of reducing the hyperglycaemia through the increased glucose utilization and inhibition of enzyme involved in carbohydrate metabolism namely α-amylase and α-glucosidase.